Wednesday, June 10, 2026
🇺🇸 FDA

pharma · TTR-mediated Amyloidosis · Hypertension · ALNY

Alnylam Netherlands

Alnylam Netherlands B.V.

Alnylam Netherlands clinical programs — 29 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Cambridge, USA HQ
2002 Founded
2,826 Employees
Public company Type
ALNY · NYSE Ticker
Company details
Status
Public
HQ
Cambridge, USA
Founded
2002
Employees
2,826
Programs
84
Drugs
37
Patents
379
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Alnylam Netherlands projects

29 ClinicalTrials.gov programs sponsored by Alnylam Netherlands.

Alnylam Netherlands has 29 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

29 programs

Clinical programs

  1. A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

    Alnylam Netherlands B.V.

    Advanced or Metastatic Hepatocellular Carcinoma

    phase 1 other active

    1 trial

  2. A Study to Evaluate ALN-HTT02 in Adult Patients with Huntington’s Disease

    Alnylam Netherlands B.V.

    Huntington’s disease

    phase 1 other active

    1 trial

  3. ALN-4285

    Alnylam Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule active

    1 trial

  4. ALN-4915

    Alnylam Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule active

    1 trial

  5. ALN-5288

    Alnylam Netherlands B.V.

    Alzheimer's Disease

    phase 1 small molecule active

    1 trial

  6. ALN-5288-001

    Alnylam Netherlands B.V.

    Alzheimer’s Disease

    phase 1 other active

    1 trial

  7. ALN-AAT

    Alnylam Netherlands B.V.

    Antitrypsin Deficiency Liver Disease

    phase 1 small molecule terminated

    1 trial

  8. ALN-AGT01

    Alnylam Netherlands B.V.

    Hypertension

    phase 1 small molecule completed

    1 trial

  9. ALN-AGT01 RVR

    Alnylam Netherlands B.V.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  10. ALN-APP

    Alnylam Netherlands B.V.

    Early-Onset Alzheimer Disease

    phase 1 small molecule active

    1 trial

  11. ALN-APP-001

    Alnylam Netherlands B.V.

    Early-onset Alzheimer's disease (EOAD)

    phase 1 other active

    1 trial

  12. ALN-BCAT

    Alnylam Netherlands B.V.

    Advanced Hepatocellular Carcinoma

    phase 1 small molecule active

    1 trial

  13. ALN-HBV

    Alnylam Netherlands B.V.

    Hepatitis B

    phase 1 small molecule terminated

    1 trial

  14. ALN-HSD

    Alnylam Netherlands B.V.

    Nonalcoholic Steatohepatitis

    phase 1 small molecule terminated

    1 trial

  15. ALN-HTT02

    Alnylam Netherlands B.V.

    Huntington's Disease

    phase 1 small molecule active

    1 trial

  16. ALN-PCS02

    Alnylam Netherlands B.V.

    Elevated LDL-Cholesterol (LDL-C)

    phase 1 small molecule completed

    1 trial

  17. ALN-PCSSC

    Alnylam Netherlands B.V.

    Hypercholesterolemia

    phase 1 small molecule completed

    1 trial

  18. ALN-TTR01

    Alnylam Netherlands B.V.

    Transthyretin Mediated Amyloidosis (ATTR)

    phase 1 small molecule completed

    1 trial

  19. ALN-TTR02

    Alnylam Netherlands B.V.

    TTR-mediated Amyloidosis

    phase 1 small molecule completed

    1 trial

  20. ALN-TTRSC (revusiran)

    Alnylam Netherlands B.V.

    TTR-mediated Amyloidosis

    phase 1 small molecule completed

    1 trial

  21. ALN-TTRSC02

    Alnylam Netherlands B.V.

    Transthyretin-mediated Amyloidosis (ATTR Amyloidosis)

    phase 1 small molecule completed

    1 trial

  22. ALN-TTRSC04

    Alnylam Netherlands B.V.

    Transthyretin-Mediated Amyloidosis

    phase 1 small molecule completed

    1 trial

  23. ALN-VSP02

    Alnylam Netherlands B.V.

    Solid Tumors

    phase 1 small molecule completed

    2 trials

  24. Computer algorithm for ATTR

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis

    phase 1 other terminated

    1 trial

  25. Givosiran

    Alnylam Netherlands B.V.

    Acute Intermittent Porphyria (AIP)

    phase 1 small molecule completed

    1 trial

  26. Pozelimab

    Alnylam Netherlands B.V.

    Healthy

    phase 1 small molecule completed

    1 trial

  27. givosiran (ALN-AS1)

    Alnylam Netherlands B.V.

    Acute Intermittent Porphyria

    phase 1 small molecule completed

    1 trial

  28. patisiran

    Alnylam Netherlands B.V.

    Polyneuropathies

    phase 1 small molecule completed

    1 trial

  29. patisiran (ALN-TTR02)

    Alnylam Netherlands B.V.

    Transthyretin (TTR)-Mediated Amyloidosis

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Alnylam Netherlands have?

29 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.